Development of pouchitis with combination therapy with peg-interferon alpha-2b and ribavirin for chronic hepatitis C in a patient with ulcerative colitis who underwent pouch surgery.
Morimoto
Kenichi
K
Yamagami
Hirokazu
H
Hosomi
Shuhei
S
Ohira
Mizuki
M
Suekane
Takehisa
T
Kamata
Noriko
N
Sogawa
Mitsue
M
Watanabe
Kenji
K
Tominaga
Kazunari
K
Watanabe
Toshio
T
Fujiwara
Yasuhiro
Y
Tamori
Akihiro
A
Oshitani
Nobuhide
N
Arakawa
Tetsuo
T
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000150:complications / Q000601:surgery*; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007081:Ileostomy / Q000379:methods*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D011092:Polyethylene Glycols; D019449:Pouchitis / Q000139:chemically induced* / Q000175:diagnosis; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b